title: Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
abstract: Vasopeptidase inhibitors possess dual inhibitory actions on neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE) and have beneficial effects on cardiac remodeling. However, the contribution of NEP inhibition to their effects is not yet fully understood. To address the role of cardiac NEP inhibition in the anti-remodeling effects of a vasopeptidase inhibitor, we examined the effects of omapatrilat on the development of cardiac remodeling in rats with left coronary artery ligation (CAL) and those on collagen synthesis in cultured fibroblast cells. In vivo treatment with omapatrilat (30 mg/kg/day for 5 weeks) inhibited cardiac NEP activity in rats with CAL, which was associated with a suppression of both cardiac hypertrophy and collagen deposition. In cultured cardiac fibroblasts, omapatrilat (10(-7) to approximately 10(-5) M) inhibited NEP activity and augmented the ANP-induced decrease in [3H]-proline incorporation. ONO-BB, an active metabolite of the NEP selective inhibitor ONO-9902, also augmented the ANP-induced response, whereas captopril, an ACE inhibitor, did not. The angiotensin I-induced increase in [3H]-proline incorporation was prevented by omapatrilat and captopril, but not by ONO-BB. The results suggest that vasopeptidase inhibitor suppressed cardiac remodeling in the setting of chronic heart failure, possibly acting through the direct inhibition of cardiac NEP. Vasopeptidase inhibitors may have therapeutic advantages over the classical ACE and NEP inhibitors alone with respect to the regression of cardiac fibrosis.
authors.affiliation: Department of Pharmacology, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Maki
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nasa
authors.forename: Kouichi
authors.initials: K
authors.lastname: Tanonaka
authors.forename: Masaya
authors.initials: M
authors.lastname: Takahashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takeo
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000378:metabolism; D005355:Fibrosis; D006333:Heart Failure / Q000188:drug therapy*; D008297:Male; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011392:Proline / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013841:Thiazepines / Q000494:pharmacology; D013997:Time Factors; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D002317:Cardiovascular Agents; D011480:Protease Inhibitors; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; D003094:Collagen; D004247:DNA; D011392:Proline; D015260:Neprilysin